Amendments to the claims:

This listing of claims replaces all prior listings of claims:

Listing of claims:

1. (Currently Amended) A compound represented by the following formula (1):



(1)

[wherein, R_{11}, R_{21}, R_{31}, and R_{41} independently denote hydrogen or methyl; R_{22}, R_{23}, R_{32}, R_{33}, R_{42}, and R_{43} independently denote a hydrogen, a linear alkyl with one to six carbon atoms, a linear alkyl with one to six carbon atoms to which a non-aromatic cyclic alkyl group or substituted or unsubstituted aromatic ring is bound, a non-aromatic cyclic alkyl, or a non-aromatic cyclic alkyl group to which a non-aromatic cyclic alkyl group or a substituted or unsubstituted aromatic ring is bound; the pairs of R_{21} and R_{22}, R_{22} and R_{23}, R_{31} and R_{32}, R_{32} and R_{33}, R_{41} and R_{42}, and R_{42} and R_{43} independently denote acyclic structures without binding or cyclic structures by binding through a linear alkylene group with a one- to five-carbon main chain, a linear alkylene group with a one- to five-carbon main chain comprising a branched chain with one to six carbons, or a linear alkylene group with a one- to five-carbon main chain comprising a ring structure of one to six carbons; X denotes hydrogen, a structure identical to that shown to the left of X, a substituted or unsubstituted alkyl or aryl group in any structure comprising a sulfur atom capable of binding with the sulfur atom in formula (1) through a disulfide bond, or a sulfur atom binding with the

sulfur atom bonded to the terminus of R_{22}, R_{23}, R_{32}, R_{33}, R_{42}, or R_{43}, and located to the left of X, via an intramolecular disulfide bond].

2. (Original) A histone deacetylase inhibitor that comprises the compound of claim 1 as an active ingredient.

3. (Original) An apoptosis-inducing agent that comprises the compound of claim 1 as an active ingredient.

4. (Original) A differentiation-inducing agent that comprises the compound of claim 1 as an active ingredient.

5. (Original) An angiogenesis inhibitor that comprises the compound of claim 1 as an active ingredient.

6. (Original) An anti-metastatic agent comprising the compound of claim 1 as an active ingredient.

7. (Original) A pharmaceutical agent for treating or preventing a disease caused by histone deacetylase 1 or 4, comprising the compound of claim 1 as an active ingredient.

8. (Original) The pharmaceutical agent of claim 7, wherein the disease caused by histone deacetylase 1 or 4 is cancer, autoimmune disease, skin disease, or infectious disease.

9. (Withdrawn) A method for producing the compound of claim 1, which comprises the steps of:
reacting a compound represented by formula (2)



(2)

(wherein, n is same as that defined in formula (1); Hal denotes a halogen atom selected from a chlorine atom, bromine atom, or iodine atom, or an allyl or alkylsulfoxy group useful for a free group; P_2 denotes a protection group for an amino group);

with a compound represented by formula (3)



(3)

(wherein R_{11}, R_{21}, R_{22}, R_{23}, R_{31}, R_{32}, R_{33}, R_{41}, R_{42}, and R_{43} are same as defined in formula (1); P_2 denotes a protection group for a carboxyl group);

in the presence of a peptide-bonding agent to obtain a compound represented by formula (4)



(4)

(wherein n, R_{11}, R_{21}, R_{22}, R_{23}, R_{31}, R_{32}, R_{33}, R_{41}, R_{42}, R_{43}, P_1, P_2, and Hal are the same as defined above);

subjecting the compound represented by formula (4) to catalytic hydrogenation, acid treatment, or hydrolysis to remove P_1 and P_2;

and then subjecting to cyclization in the presence of a peptide-bonding agent to obtain a compound represented by formula (5)



(5)

(wherein n, R_{11}, R_{21}, R_{22}, R_{23}, R_{31}, R_{32}, R_{33}, R_{41}, R_{42}, R_{43}, P_1, P_2, and Hal are the same as defined above);

or reacting a compound represented by formula (6)



(6)

(wherein R_{21}, R_{22}, R_{23}, R_{31}, R_{32}, R_{33}, R_{41}, R_{42}, R_{43}, and P_1 are the same as defined above);

with a compound represented by formula (7)



(7)

(wherein n, R_{11}, P_2, and Hal are the same as defined above);

in the presence of a peptide-bonding agent to obtain a compound represented by formula (8)



(8)

(wherein n, R_{11}, R_{21}, R_{22}, R_{23}, R_{31}, R_{32}, R_{33}, R_{41}, R_{42}, R_{43}, P_1, P_2, and Hal are the same as defined above);

subjecting the compound represented by formula (8) to catalytic hydrogenation, acid treatment, fluoride anion treatment, or hydrolysis to remove P_1 and P_2;
and then subjecting to cyclization in the presence of a peptide-bonding agent to obtain the compound represented by formula (5); following, for both process, the steps of:
reacting the compound represented by formula (5) with a reagent comprising sulfur atoms to obtain a compound represented by formula (9)



(9)

(wherein n, R_{11}, R_{21}, R_{22}, R_{23}, R_{31}, R_{32}, R_{33}, R_{41}, R_{42}, and R_{43} are the same as defined above; P_3 denotes a protection group for sulfohydryl group);

and then treating the compound represented by formula (9) with an oxidizing agent as well as ammonia or another amine.